Brand Name | Status | Last Update |
---|---|---|
belviq xr extended release | New Drug Application | 2016-07-25 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
obesity | EFO_0001073 | D009765 | E66.9 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Obesity | D009765 | EFO_0001073 | E66.9 | 4 | 3 | 5 | 4 | 3 | 18 |
Overweight | D050177 | — | E66.3 | — | — | 1 | 3 | 1 | 5 |
Weight loss | D015431 | HP_0001824 | — | — | — | — | 1 | 2 | 3 |
Weight gain | D015430 | HP_0004324 | — | 1 | 1 | — | 1 | — | 2 |
Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | — | 1 | — | 2 |
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | — | 1 |
Psychotic disorders | D011618 | — | F20.81 | — | — | — | 1 | — | 1 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Smoking cessation | D016540 | EFO_0004319 | — | — | 3 | 1 | — | — | 3 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | 1 | 1 | — | — | 3 |
Myoclonic epilepsies | D004831 | HP_0002123 | G40.4 | — | — | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cocaine-related disorders | D019970 | — | F14 | 5 | 3 | — | — | — | 7 |
Tobacco use disorder | D014029 | — | F17 | 1 | 3 | — | — | — | 3 |
Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
Tobacco smoking | D000073869 | — | — | — | 1 | — | — | — | 1 |
Sepsis | D018805 | HP_0100806 | A41.9 | 1 | 1 | — | — | — | 1 |
Muscle weakness | D018908 | HP_0001324 | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Digestive system neoplasms | D004067 | — | — | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug resistant epilepsy | D000069279 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Lorcaserin |
INN | lorcaserin |
Description | Lorcaserin is a benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine substituted at position 1 by a methyl group and a t position 6 by a chloro group. It has a role as an appetite depressant and an anti-obesity agent. It is an organochlorine compound and a benzazepine. |
Classification | Small molecule |
Drug class | serotonin receptor agonists, primarily 5-HT2 |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@H]1CNCCc2ccc(Cl)cc21 |
PDB | — |
CAS-ID | 616202-92-7 |
RxCUI | — |
ChEMBL ID | CHEMBL360328 |
ChEBI ID | 65353 |
PubChem CID | 11658860 |
DrugBank | DB04871 |
UNII ID | 637E494O0Z (ChemIDplus, GSRS) |